Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans

Rapid Development of Modified Vaccinia Virus Ankara (MVA)-Based Vaccine Candidates Against Marburg Virus Suitable for Clinical Use in Humans

Background/Objectives: Marburg virus (MARV) is the etiological agent of Marburg Virus Disease (MVD), a rare but severe hemorrhagic fever disease with high case fatality rates in humans. Smaller outbreaks have frequently been reported in countries in Africa over the last few years, and confirmed huma...

Full description

Saved in:
Bibliographic Details
Main Authors: Alina Tscherne, Georgia Kalodimou, Alexandra Kupke, Cornelius Rohde, Astrid Freudenstein, Sylvia Jany, Satendra Kumar, Gerd Sutter, Verena Krähling, Stephan Becker, Asisa Volz
Format: Article
Language:English
Published: MDPI AG 2024-11-01
Series:Vaccines
Subjects:
Modified Vaccinia virus Ankara (MVA)
viral vector vaccine
emerging viruses
rapid vaccine development
Marburg virus
Online Access:https://www.mdpi.com/2076-393X/12/12/1316
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items